India, Oct. 28 -- The U.S. Department of Health and Human Services has temporarily allowed licensed pharmacies and physicians to compound certain unapproved peptide ingredients while regulators consider whether to formally permit their use in compounded medicines.
The interim policy covers six peptides, including BPC-157 and TB-500, which are promoted for tissue repair and other wellness uses. It also includes epitalon, KPV, MOTS-c and Semax, marketed for conditions ranging from insomnia and inflammation to obesity and migraines.
HHS said it would not take enforcement action against compounders using the peptides if they meet requirements covering ingredient quality, manufacturing standards, safety reporting, labeling and patient-specific...